Seer Q3 2026 slides: scientific gains offset by revenue guidance cut

Seer, Inc. (SEER) reported Q3 2026 revenue of $4.0M, flat YoY but up 29% QoQ. It cut FY2026 revenue guidance to $13.5M-$14.5M from $16M-$18M, citing funding constraints. Shares fell 3.73% in after-hours trading to $1.55. The company highlighted scientific progress but faces commercial growth challenges.

Original reporting
Published Nov 10, 2026, 10:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SEER
Bearish
high confidence
Mentioned
$SEER
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SEERBearishMed
01

Why it matters

Guidance reduction and funding constraints suggest near‑term revenue weakness, but long‑term AI‑proteomics potential remains.

02

Market read

Earnings release with guidance cut is primary news for SEER, likely driving short‑term price decline.

03

What to watch

Strong cash position of $198M and recent share repurchase could support the stock despite lower guidance.

Relevance 7/10Novelty 8/10Timing: after-hours today

Background

Seer Inc. (NASDAQ:SEER) presented its Q3 2026 earnings, highlighting scientific progress but reduced revenue outlook.

Company-level read

Ticker impact

$SEERBearishHigh confidence
Context

Seer reported Q3 2026 results and cut full-year revenue guidance, causing a 3.73% after‑hours share decline.

Expected impact

downward pressure as investors price in reduced revenue outlook

Evidence & confidence

Revenue guidance lowered by ~19% due to funding constraints; shares already fell in after‑hours trading.

Market effects

Proteomics and biotech funding environment faces headwinds, may dampen sector sentiment.

US biotech investors may become more risk‑averse.

Limited to niche proteomics market; minimal broader market effect.

Counterpoint

If AI‑driven demand for deep proteomics accelerates, the guidance cut may be temporary and upside possible.

Key entities

  • Seer Inc.

    US‑listed proteomics platform provider reporting earnings and guidance cut.

  • Omid Farokhzad

    CEO of Seer who commented on long‑term prospects.

Related articles

$SEERMed

Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance REDWOOD CITY, Calif. – November 10, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced fin

$SEERMed

Seer wins ITC staff backing for import ban on Nanomics products

Seer, Inc. (SEER) announced that the U.S. International Trade Commission's staff recommended an import ban on Nanomics' products, alleging patent infringement. The ITC is expected to make a final decision by year-end. Seer also reported recent patent victories in the U.S. and Europe. The company develops proteomics technology and is involved in a related lawsuit against Nanomics.

$SEERMedAI 8/10

Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million

Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.